Powered by

Revive Therapeutics Appoints Dr. Scott Friedman, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases

Mar 22, 2017 - Marketwired
Board and Executive Moves

TORONTO, ONTARIO--(Marketwired - March 22, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that Dr. Scott Friedman, M.D., will join the Company as a Scientific Advisor for cannabinoid-based therapeutics targeting liver diseases.

"I am pleased that Dr. Friedman has joined Revive to assist with adva

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox